https://www.selleckchem.com/pr....oducts/bms-986158.ht
7% vs 8.8%, p less then 0.001). Children carrying homozygous M694V mutation had significantly earlier age of disease onset and severe disease course (p less then 0.001). Forty-four patients (2.6%) were colchicine resistant and most of them were carrying homozygous M694V mutation. Sixteen colchicine-resistant patients were treated with anakinra while 28 received canakinumab. Juvenile idiopathic arthritis (JIA) and immunoglobulin A vasculitis were the most commonly seen associated diseases and the patients with a concomitant diseas
Like
Comment
Share
